FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 208 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma March 5, 2024 Liquid Biopsies for Cancer: What to Know and What to Expect November 3, 2022 Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy... July 12, 2024 FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications December 10, 2021 Load more HOT NEWS New Risk Model Aims to Reduce Breast Cancer Disparities in Black... A Diagnosis of Advanced Lung Cancer Is Not a Death Sentence ¿Las gammagrafías óseas muestran el cáncer? Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable...
